secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tonix Pharmaceuticals Holding Corp. (TNXP)
CIK:        0001430306
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0001839882-23-030323
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tonix Q3 net loss $28M ($1.83/shr); cash drops to $6.9M; phase 3 fibromyalgia data due Dec 2023
--------------------------------------------------------------------------------

- Net product revenue of $4.0M in first quarter after acquiring Zembrace/Tosymra in June 2023.
- Cash and equivalents $6.9M at Sep 30, 2023 vs $120.2M at Dec 31, 2022.
- Public offerings in Aug and Sep 2023 raised net proceeds of $6.3M and $4.0M respectively.
- Topline Phase 3 RESILIENT trial (TNX-102 SL) for fibromyalgia expected late December 2023.
- Topline Phase 2 PREVENTION study (TNX-1900) for chronic migraine expected early December 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1430306/000183988223030323/0001839882-23-030323-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1430306/000183988223030323/tnxp-8k_110923.htm
  HTML page:      https://secwatch.observer/filing/0001839882-23-030323

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer